Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery
Completed · Phase 2/Phase 3
Conditions studied: Congenital Heart Defects
In brief
We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart defects.
Key facts
- Study ID
- NCT00226369
- Run by
- Boston Children's Hospital
- People needed
- 242
- Starts
- 1997-12-01
- Expected to finish
- 2001-06-01
- Last updated by the study team
- 2010-02-12
Who can join
Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital Boston — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.